Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Regulation of Tumor necrosis factor Receptor-Associated Factor 1 (TRAF1) by Protein Kinase N1 (PKN1): implications for lymphoma

EF 2015-16

Résumé
Lymphomas, the 10th most common cause of cancer worldwide, are cancerous forms of white blood cells, also known as lymphocytes. Although there are many treatment options, the 5-year survival rate is still only 67%, and new treatments are needed for cancers that do not respond to current therapy. Past studies have illustrated that approximately half of the lymphomas express unusually high amounts of a protein calledTumor necrosis factor Receptor-Associated Factor 1 (TRAF1), and Watts' team has shown that by lowering the amount of TRAF1 directly with an approach, known as RNA interference (RNAi), cancer cells were more susceptible to death after exposing them to an approved cancer drug, Erwinase, which acts by inducing nutrient stress in the tumor micro-environment. Understanding that RNAi is not practical in human therapy, Watts' team sought another approach to lowering TRAF1 levels. Specifically, Watts' team has identified an enzyme that is required in the cancer cells to keep TRAF1 levels high, and suggested the possibility of lowering the levels of TRAF1 through this enzyme indirectly as a new therapy for lymphoma. Hence, the following proposed study will work towards the development of a new cancer drug, based on finding a specific enzyme inhibitor to lower TRAF1 levels in lymphoma, thus sensitizing them to Erwinase. To conduct this study, we will elucidate the mechanism of regulation of TRAF1 by this enzyme to validate it as a drug target. This study will then test the effect of this enzyme inhibitor in combination with other recently approved lymphoma drugs to assess for synergistic therapeutic effects. Finally, to conclude the study, we will aim to validate these findings in primary lymphoma cells.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
349862
Name
Ting Kenneth K
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Regulation of Tumor necrosis factor Receptor-Associated Factor 1 (TRAF1) by Protein Kinase N1 (PKN1): implications for lymphoma
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Chronic Lymphocytic Leukemia; Erwinase; Glutamine; Lymphoma; Nf-Kappa-B; Nutrient Stress; Phosphorylation; Protein Kinase N1 (Pkn1); Shrna; Tnfr Associated Factors (Trafs)
Abstract
Lymphomas, the 10th most common cause of cancer worldwide, are cancerous forms of white blood cells, also known as lymphocytes. Although there are many treatment options, the 5-year survival rate is still only 67%, and new treatments are needed for cancers that do not respond to current therapy. Past studies have illustrated that approximately half of the lymphomas express unusually high amounts of a protein calledTumor necrosis factor Receptor-Associated Factor 1 (TRAF1), and Watts' team has shown that by lowering the amount of TRAF1 directly with an approach, known as RNA interference (RNAi), cancer cells were more susceptible to death after exposing them to an approved cancer drug, Erwinase, which acts by inducing nutrient stress in the tumor micro-environment. Understanding that RNAi is not practical in human therapy, Watts' team sought another approach to lowering TRAF1 levels. Specifically, Watts' team has identified an enzyme that is required in the cancer cells to keep TRAF1 levels high, and suggested the possibility of lowering the levels of TRAF1 through this enzyme indirectly as a new therapy for lymphoma. Hence, the following proposed study will work towards the development of a new cancer drug, based on finding a specific enzyme inhibitor to lower TRAF1 levels in lymphoma, thus sensitizing them to Erwinase. To conduct this study, we will elucidate the mechanism of regulation of TRAF1 by this enzyme to validate it as a drug target. This study will then test the effect of this enzyme inhibitor in combination with other recently approved lymphoma drugs to assess for synergistic therapeutic effects. Finally, to conclude the study, we will aim to validate these findings in primary lymphoma cells.
Competitiondate
201512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Ting, Kenneth K
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~